24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 689 participants.

Also called NCT02243176

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 689 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02243176
Other papers using this trial's data
  • Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study) Diabetes, obesity & metabolism, 2017-11 DOI, PubMed 28296055

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02243176. Randomized; no masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2017-04-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
Acronym
SMART
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Acarbose
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02243176
Content hash
42f65be73281557d02ef04c7fb0adbdc17126f1378850dda9a251e75b456288c